[{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Spaulding Rehabilitation Hospital | Albert Einstein Healthcare Network | Indiana University | Craig Hospital | TIRR Memorial Hermann","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Baylor College of Medicine \/ Spaulding Rehabilitation Hospital | Albert Einstein Healthcare Network | Indiana University | Craig Hospital | TIRR Memorial Hermann","highestDevelopmentStatusID":"10","companyTruncated":"Baylor College of Medicine \/ Spaulding Rehabilitation Hospital | Albert Einstein Healthcare Network | Indiana University | Craig Hospital | TIRR Memorial Hermann"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Citrulline","moa":"Atherogenic","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ceftaroline Fosamil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor College of Medicine \/ Allergan","highestDevelopmentStatusID":"7","companyTruncated":"Baylor College of Medicine \/ Allergan"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Rare Diseases Clinical Research Network | Neogenis Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Baylor College of Medicine \/ Rare Diseases Clinical Research Network | Neogenis Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Rare Diseases Clinical Research Network | Neogenis Laboratories"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Baylor College of Medicine \/ Allergan","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Allergan"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Center for Cell and Gene Therapy, Baylor College of Medicine | Alex's Lemonade Stand Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Center for Cell and Gene Therapy, Baylor College of Medicine | Alex's Lemonade Stand Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Center for Cell and Gene Therapy, Baylor College of Medicine | Alex's Lemonade Stand Foundation"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fidaxomicin","moa":"DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Baylor College of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Effector Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Baylor College of Medicine \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Effector Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Baylor College of Medicine \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Baylor College of Medicine \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Baylor College of Medicine \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Kuur Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Ganglioside GD2 (GD2)","graph1":"Oncology","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Kuur Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Ganglioside GD2 (GD2)","graph1":"Oncology","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Pharmacosmos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","graph1":"Hematology","graph2":"Phase III","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Baylor College of Medicine \/ Pharmacosmos Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Baylor College of Medicine \/ Pharmacosmos Therapeutics"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Tessa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"TT11X","moa":"Lymphocyte activation antigen CD30 (TNFRSF8)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Baylor College of Medicine \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Merck & Co | The Methodist Hospital Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Merck & Co | The Methodist Hospital Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Baylor College of Medicine \/ Merck & Co | The Methodist Hospital Research Institute"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baylor College of Medicine \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Baylor College of Medicine \/ Genentech"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Baylor College of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Relypsa","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Relypsa","highestDevelopmentStatusID":"11","companyTruncated":"Baylor College of Medicine \/ Relypsa"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"LifeNet Health","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Dermacell","moa":"Progenitor cell","graph1":"Podiatry","graph2":"Phase II\/ Phase III","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ LifeNet Health","highestDevelopmentStatusID":"9","companyTruncated":"Baylor College of Medicine \/ LifeNet Health"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Biological E","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Biological E","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Biological E"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Center for Cell and Gene Therapy, Baylor College of Medicine | AlloVir | The Methodist Hospital Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoVSTs","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Center for Cell and Gene Therapy, Baylor College of Medicine | AlloVir | The Methodist Hospital Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Center for Cell and Gene Therapy, Baylor College of Medicine | AlloVir | The Methodist Hospital Research Institute"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Sleep","graph2":"Phase IV","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Baylor College of Medicine \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Texas Department of State Health Services | Usona Institute | AIM Youth Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Texas Department of State Health Services | Usona Institute | AIM Youth Mental Health","highestDevelopmentStatusID":"8","companyTruncated":"Baylor College of Medicine \/ Texas Department of State Health Services | Usona Institute | AIM Youth Mental Health"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MCB-613","moa":"Steroid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Baylor College of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Sanofi | Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Fresolimumab","moa":"Transforming growth factor beta-1 | Transforming growth factor beta-3 | Transforming growth factor beta-2","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Sanofi | Oregon Health and Science University","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Sanofi | Oregon Health and Science University"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Skye Biologics Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Activematrix","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Skye Biologics Holdings","highestDevelopmentStatusID":"11","companyTruncated":"Baylor College of Medicine \/ Skye Biologics Holdings"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"AlloVir","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"ALVR106","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ AlloVir","highestDevelopmentStatusID":"4","companyTruncated":"Baylor College of Medicine \/ AlloVir"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Expanded Collaboration","leadProduct":"CoV RBD219-N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CoV RBD219-N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CoV RBD219-N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Baylor College of Medicine \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Glycosbio Nutritional Supplement","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Harris Health System | Dan L Duncan Comprehensive Cancer Center | Baylor St. Luke's Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Harris Health System | Dan L Duncan Comprehensive Cancer Center | Baylor St. Luke's Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Baylor College of Medicine \/ Harris Health System | Dan L Duncan Comprehensive Cancer Center | Baylor St. Luke's Medical Center"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Prolacta Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Human Milk Cream","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Baylor College of Medicine \/ Prolacta Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Prolacta Bioscience"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"nCoV-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Prolacta Bioscience | Medical University Innsbruck | University of Texas Health Science Center at Houston | Michigan State University | Akron Children's Hospital | Timpanogos Regional Hospital | Orlando Health | St. Louis Children's Hospital | Baylor Scot","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"ProlactCR","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Baylor College of Medicine \/ Prolacta Bioscience | Medical University Innsbruck | University of Texas Health Science Center at Houston | Michigan State University | Akron Children's Hospital | Timpanogos Regional Hospital | Orlando Health | St. Louis Children's Hospital | Baylor Scot","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Prolacta Bioscience | Medical University Innsbruck | University of Texas Health Science Center at Houston | Michigan State University | Akron Children's Hospital | Timpanogos Regional Hospital | Orlando Health | St. Louis Children's Hospital | Baylor Scot"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Center for Cell and Gene Therapy, Baylor College of Medicine | The Methodist Hospital Research Institute | Children's Hospital Los Angeles | Duke University | Hackensack Meridian Health | New York Medical College | UT Southwestern Medical Center | Childre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Trivirus-Specific CTLs","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor College of Medicine \/ Center for Cell and Gene Therapy, Baylor College of Medicine | The Methodist Hospital Research Institute | Children's Hospital Los Angeles | Duke University | Hackensack Meridian Health | New York Medical College | UT Southwestern Medical Center | Childre","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Center for Cell and Gene Therapy, Baylor College of Medicine | The Methodist Hospital Research Institute | Children's Hospital Los Angeles | Duke University | Hackensack Meridian Health | New York Medical College | UT Southwestern Medical Center | Childre"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Mead Johnson Nutrition | The Children's Nutrition Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Mead Johnson Nutrition | The Children's Nutrition Research Center","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Mead Johnson Nutrition | The Children's Nutrition Research Center"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Immunai","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Baylor College of Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Baylor College of Medicine \/ Baylor College of Medicine"}]
Find Clinical Drug Pipeline Developments & Deals by Baylor College of Medicine
Details :
Psilocybin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stress Disorders, Post-Traumatic.
Details :
HPV Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uterine Cervical Neoplasms.
Details :
Atezolizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colonic Neoplasms.
Details :
Anti-GD2 CAR NKT-Cell Therapy targeting BTG1 which is identified as a novel molecular target that can be used to enhance the potency of natural killer T (NKT)- and T cell-based cancer immunotherapy. It is being developed for relapsed/refractory neuroblas...
Details :
Through this collaboration, BridgeBio will work with Baylor College of Medicine to identify and translate promising innovations into potential therapies for patients with genetically driven diseases.
Details :
Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Iron-Deficiency.
Details :
Pembrolizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Details :
Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor 4A (eIF4A) mediated translation used in solid tumor indications, including triple negative breast cancer.